Fig. 1: MELK mRNA expression is increased in DLBCL and MCL patients, which is associated with poor survival in DLBCL. | Blood Cancer Journal

Fig. 1: MELK mRNA expression is increased in DLBCL and MCL patients, which is associated with poor survival in DLBCL.

From: Maternal embryonic leucine zipper kinase is a novel target for diffuse large B cell lymphoma and mantle cell lymphoma

Fig. 1

a MELK gene expression levels of B cell samples (n = 33), patients with ABC-DLBCL (n = 190), patients with GCB-DLBCL (n = 212) and patients with unclassified DLBCL (n = 67) were obtained from the publicly available microarray datasets GSE10846 and GSE56315. Mean expression ± SD is shown in red. ***p < 0.001. b The prognostic value of MELK was determined in DLBCL patients (93 ABC, 108 GCB, and 32 unclassified DLBCL patients) receiving R-CHOP treatment from the Lenz cohort (n = 233) using Maxstat analysis (cut-off value used is 9.17). c MELK gene expression levels of patients with indolent (n = 7) and aggressive MCL (n = 15) were obtained from the GSE16455 dataset. Mean expression ± SD is shown in red. *p < 0.05 and **p < 0.01. d Immunohistochemical analysis of MELK expression in a DLBCL patient. A ×4 and ×20 magnification is shown. e Percentage of MELK positive lymphoma cells was counted in 27 DLBCL patients treated with R-CHOP and plotted against the estimated prognosis according to the R-IPI-score of the patients.

Back to article page